<DOC>
	<DOCNO>NCT02022254</DOCNO>
	<brief_summary>This trial conduct Europe Asia . The aim trial investigate influence semaglutide pharmacokinetics ( exposure trial drug body ) pharmacodynamics ( effect investigate drug body ) warfarin pharmacokinetics metformin healthy subject .</brief_summary>
	<brief_title>Influence Semaglutide Pharmacokinetics Pharmacodynamics Warfarin Pharmacokinetics Metformin Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Male female , age 18 55 year ( inclusive ) time sign informed consent Body mass index ( BMI ) 23 30 kg/m^2 ( inclusive ) Female pregnant , breastfeed intend become pregnant childbearingpotential use adequate contraceptive method duration trial 5 week follow last dose semaglutide . Adequate contraceptive measure implant , injectables , combine oral contraceptive , hormonal intrauterine device , sexual abstinence vasectomise partner Any clinically significant disease history , opinion investigator , systemic organ disease include : pulmonary , gastrointestinal , hepatic , neurologic , renal , genitourinary endocrine , dermatologic hematologic disease Use prescription nonprescription systemic topical medicinal product ( include routine nonroutine vitamin herbal product , exclude paracetamol contraceptive ) within 3 week ( within 5 halflives medicinal product , whichever long ) prior Visit 2 Smoking , drug alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>